Genelux posts wider-than-expected Q2 loss on higher R&D expenses

Genelux

13/08/2026 21:29

Overview
US immuno-oncology firm's Q2 net loss widened, missing analyst expectations
Income from operations for Q2 missed analyst expectations
Operating expenses rose due to higher Phase 3 trial costs

Outlook
Genelux expects topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer trial in 2H26
Company anticipates additional dose-escalation updates from systemic Olvi-Vec studies in 2026
Genelux expects cash and equivalents to fund operations into 1Q27

Result Drivers
PHASE 3 TRIAL COSTS - Co said higher R&D expenses were primarily due to increased clinical trial costs for the Phase 3 OnPrime/GOG-3076 registration trial
STOCK COMPENSATION - Slight increase in G&A expenses was mainly due to higher stock compensation

Company press release: ID:nGNX3Y4JqX

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$9.47 mln
$8.77 mln (6 Analysts)
Q2 Income from Operations
Miss
-$9.65 mln
-$8.95 mln (6 Analysts)
Q2 Operating Expenses
 
$9.65 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Genelux Corporation is $16.00, about 492.6% above its August 12 closing price of $2.70

Reuters Recommended Reads
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 13 - Aktis Oncology Q2 net loss widens on higher R&D, administrative costs
Aug 13 - Pyxis Oncology Q2 loss widens on increased administrative costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)